Connecting you to content on EBSCOhost

Works by Sawa, Nobuhiko

Results: 6

1

Dyspnea and the Varying Pathophysiologic Manifestations of Chronic Obstructive Pulmonary Disease Evaluated by Cardiopulmonary Exercise Testing With Arterial Blood Analysis.

Published in:

Frontiers in Physiology, 2018, p. 1, doi. 10.3389/fphys.2018.01293

By:

Hiroyuki Kagawa;
Keisuke Miki;
Seigo Kitada;
Mari Miki;
Kenji Yoshimura;
Yohei Oshitani;
Kohei Nishida;
Nobuhiko Sawa;
Kazuyuki Tsujino;
Ryoji Maekura

Publication type:

Article

2

Monitoring antibody binding to T cells in a pembrolizumab‐treated patient with lung adenocarcinoma on hemodialysis.

Published in:

Thoracic Cancer, 2019, v. 10, n. 11, p. 2183, doi. 10.1111/1759-7714.13197

By:

Osa, Akio;
Uenami, Takeshi;
Naito, Yujiro;
Hirata, Haruhiko;
Koyama, Shohei;
Takimoto, Takayuki;
Shiroyama, Takayuki;
Futami, Shinji;
Nakatsubo, Saeko;
Sawa, Nobuhiko;
Yano, Yukihiro;
Nagatomo, Izumi;
Takeda, Yoshito;
Mori, Masahide;
Kida, Hiroshi;
Kumanogoh, Atsushi

Publication type:

Article

3

Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.

Published in:

2020

By:

Hosoya, Kazutaka;
Fujimoto, Daichi;
Morimoto, Takeshi;
Kumagai, Toru;
Tamiya, Akihiro;
Taniguchi, Yoshihiko;
Yokoyama, Toshihide;
Ishida, Tadashi;
Hirano, Katsuya;
Matsumoto, Hirotaka;
Kominami, Ryota;
Tomii, Keisuke;
Suzuki, Hidekazu;
Hirashima, Tomonori;
Uchida, Junji;
Morita, Mitsunori;
Kanazu, Masaki;
Sawa, Nobuhiko;
Makio, Takeshi;
Hara, Satoshi

Publication type:

journal article

4

Pulmonary rehabilitation for COPD improves exercise time rather than exercise tolerance: effects and mechanisms.

Published in:

International Journal of COPD, 2017, v. 12, p. 1061, doi. 10.2147/COPD.S131061

By:

Keisuke Miki;
Ryoji Maekura;
Seigo Kitada;
Mari Miki;
Kenji Yoshimura;
Hiroshi Yamamoto;
Toshiko Kawabe;
Hiroyuki Kagawa;
Yohei Oshitani;
Akitoshi Satomi;
Kohei Nishida;
Nobuhiko Sawa;
Kimiko Inoue

Publication type:

Article

5

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.

Published in:

Investigational New Drugs, 2020, v. 38, n. 1, p. 211, doi. 10.1007/s10637-019-00882-5

By:

Kawachi, Hayato;
Tamiya, Motohiro;
Tamiya, Akihiro;
Ishii, Seigo;
Hirano, Katsuya;
Matsumoto, Hirotaka;
Fukuda, Yasushi;
Yokoyama, Toshihide;
Kominami, Ryota;
Fujimoto, Daichi;
Hosoya, Kazutaka;
Suzuki, Hidekazu;
Hirashima, Tomonori;
Kanazu, Masaki;
Sawa, Nobuhiko;
Uchida, Junji;
Morita, Mitsunori;
Makio, Takeshi;
Hara, Satoshi;
Kumagai, Toru

Publication type:

Article

6

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).

Published in:

Investigational New Drugs, 2019, v. 37, n. 6, p. 1266, doi. 10.1007/s10637-019-00843-y

By:

Tamiya, Motohiro;
Tamiya, Akihiro;
Hosoya, Kazutaka;
Taniguchi, Yoshihiko;
Yokoyama, Toshihide;
Fukuda, Yasushi;
Hirano, Katsuya;
Matsumoto, Hirotaka;
Kominami, Ryota;
Suzuki, Hidekazu;
Hirashima, Tomonori;
Uchida, Junji;
Morita, Mitsunori;
Kanazu, Masaki;
Sawa, Nobuhiko;
Kinoshita, Yoshinori;
Hara, Satoshi;
Kumagai, Toru;
Fujimoto, Daichi

Publication type:

Article